SCHEMBL6209857

SCHEMBL6209857

CC(C)(C)OC(=O)N1CCCC(O)(C=CCO)C1c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 9/20 0.41
▸ NR1H3 Q13133 8/20 0.41
▸ RXRA P19793 6/20 0.41
▸ ABCB1 P08183 1/20 0.41
▸ HCRTR2 O43614 1/20 0.40
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ RIPK1 Q13546 1/20 0.39
▸ KLK7 P49862 1/20 0.38
▸ KDM1A O60341 1/20 0.37
▸ UCHL1 P09936 1/20 0.37
▸ RORC P51449 1/20 0.37
▸ GPR119 Q8TDV5 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5783560 1.00 NR1H2 (0.41) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL5783564 1.00 NR1H2 (0.41) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL8157917 0.90 MEN1 (0.40) MEN1KMT2ARORC
SCHEMBL8157922 0.90 MEN1 (0.40) MEN1KMT2ARORC
SCHEMBL8459509 0.83 CHRM2 (0.37) MEN1KMT2AALDH1A1TSHRL3MBTL1
SCHEMBL9024216 0.79 NR1H2 (0.47) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL8156074 0.78 NR1H2 (0.37) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL8156067 0.78 NR1H2 (0.37) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL7919390 0.78 NR1H2 (0.39) NR1H2NR1H3RXRAABCB1HCRTR2
SCHEMBL8156075 0.78 NR1H2 (0.37) NR1H2NR1H3RXRAABCB1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0942733-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING COGNITIVE DISORDERS MERCK SHARP & DOHME (GB) 2005-04-27 — — EP disclosed
EP-0941093-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS WITH ANXIETY MERCK SHARP & DOHME (GB) 2005-02-09 — — EP disclosed
EP-0941092-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MAJOR DEPRESSIVE DISORDERS MERCK SHARP & DOHME (GB) 2004-12-29 — — EP disclosed
EP-0942732-B1 USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING MOVEMENT DISORDERS MERCK SHARP & DOHME (GB) 2004-11-17 — — EP disclosed
Send feedback